Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
09 März 2021 - 5:16PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
9 March 2021 15:00 GMT
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 5 March 2021,
certain Persons Discharging Managerial Responsibilities of the
Company (PDMRs) were granted awards of the Company's ordinary
shares of $0.25 each (Ordinary Shares) under the terms of the
AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca
Performance Share Plan (AZPSP), as detailed in the table
below.
PDMR
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
Pascal Soriot
|
16,944
|
106,655
|
£68.44
|
Marc Dunoyer
|
9,057
|
51,828
|
£68.44
|
The AZDBP award represents the portion of each PDMR's annual bonus
for 2020 that they are required to defer into shares. The Ordinary
Shares granted under the AZDBP are subject to a three-year holding
period and are due to vest on the third anniversary of
grant.
The AZPSP award is subject to a combination of performance measures
focused on scientific, commercial and financial performance. An ESG
measure has also been introduced to the 2021 AZPSP performance
measures, which focuses on the delivery of AstraZeneca's Ambition
Zero Carbon commitments and underlines the importance the Company
places on eliminating Scope 1 and Scope 2 greenhouse gas emissions
by 2025. The performance measures will be assessed over a
three-year performance period (1 January 2021 to 31 December 2023).
The Ordinary Shares granted under the AZPSP are subject to a
two-year holding period following the performance period, and are
due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can
be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2020, which is
available on the Company's website at www.astrazeneca.com/annualreport2020.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Pascal Soriot
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Executive Officer
|
b)
|
Initial notification /Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus Plan
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
£68.44
|
123,599
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
5 March 2021
|
f)
|
Place of the transaction
|
Outside a trading venue
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Marc Dunoyer
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Financial Officer
|
b)
|
Initial notification /Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus Plan
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
£68.44
|
60,885
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
5 March 2021
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
09 March 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024